1. Home
  2. RSF vs XLO Comparison

RSF vs XLO Comparison

Compare RSF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Capital and Income Fund

RSF

RiverNorth Capital and Income Fund

HOLD

Current Price

$14.66

Market Cap

59.0M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$7.79

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSF
XLO
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.0M
49.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RSF
XLO
Price
$14.66
$7.79
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
10.6K
29.0K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
10.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$168.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$14.23
$0.46
52 Week High
$15.07
$9.25

Technical Indicators

Market Signals
Indicator
RSF
XLO
Relative Strength Index (RSI) 50.35 42.24
Support Level $14.36 $7.40
Resistance Level $14.70 $8.97
Average True Range (ATR) 0.07 0.40
MACD 0.00 -0.11
Stochastic Oscillator 47.06 13.11

Price Performance

Historical Comparison
RSF
XLO

About RSF RiverNorth Capital and Income Fund

RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: